Ivonescimab NMPA Approval Signals Breakthrough ...

Ivonescimab, a pioneering PD-1/VEGF bispecific antibody developed by Akeso, Inc., secured approval from China’s National Medical Products Administration (NMPA) on April 25, 2025, for first-line treatment of PD-L...